FDAClass IIMay 31, 2023

buPROPrion Hydrochloride Extended-Release Tablets recall: Failed Dissolution

buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86

Why was buPROPrion Hydrochloride Extended-Release Tablets recalled?

Failed Dissolution Specifications; during stability testing

What should I do if I have this product?

Review the official FDA enforcement record for current instructions.

What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.

Is my product affected?

Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.

Which lot codes, UPCs or models are affected?

Lots: HAC2240A, Exp 05/2023; HAC3162A, Exp 07/2023

Product
buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86
Recalling firm
SUN PHARMACEUTICAL INDUSTRIES INC
Quantity
5,344 Bottles
Distribution
Nationwide in the U.S.A
Recall date
May 31, 2023
Classification
Class II
Status
Terminated
Agency
FDA (drug)
Open FDA enforcement record Latest recalls